GYRE

Gyre is a genuinely profitable, commercial-stage biopharma — a rarity in small-cap pharma — anchored by ETUARY (pirfenidone) for IPF in the PRC, now supplemented by Etorel (nintedanib) and Contiva (avatrombopag). The quality of the P&L is real: 87.4% gross margin, positive operating income ($11.5M) and, critically, a clean balance sheet — $23.9M total liabilities against $106M equity (0.22x), $37.1M cash (up 214%), and no meaningful debt. FY2025 revenue grew 10.2% to $117M. This is not a cash-burning story; operating cash flow is positive and current assets ($102M) dwarf current liabilities ($18.3M). That solvency is what keeps this a hold rather than an avoid.

But the profit trend is going the wrong way and the price already ignores it. Net income fell 44.8% to $9.88M, diluted EPS dropped 60% to $0.02, and operating income slipped 28.9% — so the growth is top-line only, with margins compressing. At $7.34 that leaves a P/E of 367; even on the more forgiving 6.1x sales, you're paying a premium multiple for ~10% growth and shrinking earnings. The five-year net-income history (-$87.9M, +$4.31M, -$85.5M, +$17.9M, +$9.88M) shows how lumpy and unreliable the bottom line has been, so the P/E is close to meaningless and the whole valuation rests on pipeline optionality, not current cash flows.